Abstract
Artificial activators designed using transcription activator–like effector (TALE) technology have broad utility, but previous studies suggest that these monomeric proteins often exhibit low activities. Here we demonstrate that TALE activators can robustly function individually or in synergistic combinations to increase expression of endogenous human genes over wide dynamic ranges. These findings will encourage applications of TALE activators for research and therapy, and guide design of monomeric TALE-based fusion proteins.
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Functional genetic variants can mediate their regulatory effects through alteration of transcription factor binding
Nature Communications Open Access 02 August 2019
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Rent or buy this article
Get just this article for as long as you need it
$39.95
Prices may be subject to local taxes which are calculated during checkout


References
Joung, J.K. & Sander, J.D. Nat. Rev. Mol. Cell Biol. 14, 49–55 (2012).
Mussolino, C. & Cathomen, T. Curr. Opin. Biotechnol. 23, 644–650 (2012).
Miller, J.C. et al. Nat. Biotechnol. 29, 143–148 (2011).
Zhang, F. et al. Nat. Biotechnol. 29, 149–153 (2011).
Geissler, R. et al. PLoS ONE 6, e19509 (2011).
Garg, A., Lohmueller, J.J., Silver, P.A. & Armel, T.Z. Nucleic Acids Res. 40, 7584–7595 (2012).
Tremblay, J.P., Chapdelaine, P., Coulombe, Z. & Rousseau, J. Hum. Gene Ther. 23, 883–890 (2012).
Wang, Z. et al. Angew. Chem. Int. Edn. Engl. 51, 8505–8508 (2012).
Cong, L., Zhou, R., Kuo, Y.C., Cunniff, M. & Zhang, F. Nat. Commun. 3, 968 (2012).
Bultmann, S. et al. Nucleic Acids Res. 40, 5368–5377 (2012).
Cermak, T. et al. Nucleic Acids Res. 39, e82 (2011).
Reyon, D. et al. Nat. Biotechnol. 30, 460–465 (2012).
Liu, P.Q. et al. J. Biol. Chem. 276, 11323–11334 (2001).
Carey, M., Lin, Y.S., Green, M.R. & Ptashne, M. Nature 345, 361–364 (1990).
Khalil, A.S. et al. Cell 150, 647–658 (2012).
Deans, T.L., Cantor, C.R. & Collins, J.J. Cell 130, 363–372 (2007).
Tigges, M., Marquez-Lago, T.T., Stelling, J. & Fussenegger, M. Nature 457, 309–312 (2009).
Xie, Z., Wroblewska, L., Prochazka, L., Weiss, R. & Benenson, Y. Science 333, 1307–1311 (2011).
Culler, S.J., Hoff, K.G. & Smolke, C.D. Science 330, 1251–1255 (2010).
Auslander, S., Auslander, D., Muller, M., Wieland, M. & Fussenegger, M. Nature 487, 123–127 (2012).
Rosenbloom, K.R. et al. Nucleic Acids Res. 40, D912–D917 (2012).
Acknowledgements
This work was supported by a US National Institutes of Health (NIH) Director's Pioneer Award DP1 OD006862 (J.K.J.), NIH P50 HG005550 and R01 NS073124 (J.K.J.), the Jim and Ann Orr Massachusetts General Hospital Research Scholar Award (J.K.J.), a US National Science Foundation Graduate Research Fellowship (M.L.M.), and NIH T32 CA009216 (J.D.S.). We thank J. Foley for technical assistance with construction of TALE-activator plasmids, R. Mylvaganam for technical assistance with flow cytometry, and the Massachusetts General Hospital Nucleic Acid Quantitation Core (supported by NIH P30 NS45776) for assistance with performing real-time reverse-transcription–PCR assays.
Author information
Authors and Affiliations
Contributions
M.L.M., S.J.L., D.R., J.F.A., Y.F., J.D.S. and J.K.J. designed the experiments. M.L.M., S.J.L., D.R., J.F.A. and Y.F. performed experiments. M.L.M. and J.K.J. wrote the manuscript.
Corresponding author
Ethics declarations
Competing interests
J.K.J. has a financial interest in Transposagen Biopharmaceuticals. J.K.J.'s interests were reviewed and are managed by Massachusetts General Hospital and Partners HealthCare in accordance with their conflict of interest policies.
Supplementary information
Supplementary Text and Figures
Supplementary Figures 1–2, Supplementary Tables 1–2, Supplementary Discussion (PDF 377 kb)
Rights and permissions
About this article
Cite this article
Maeder, M., Linder, S., Reyon, D. et al. Robust, synergistic regulation of human gene expression using TALE activators. Nat Methods 10, 243–245 (2013). https://doi.org/10.1038/nmeth.2366
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/nmeth.2366
This article is cited by
-
PIWI-Interacting RNA (piRNA) and Epigenetic Editing in Environmental Health Sciences
Current Environmental Health Reports (2022)
-
Functional genetic variants can mediate their regulatory effects through alteration of transcription factor binding
Nature Communications (2019)